Abstract
Objectives
Cardiovascular risk is associated with cognitive decline and this effect is attributed to brain pathology, including white matter hyperintensity (WMH) burden. Low-dose aspirin is frequently recommended for reducing vascular events. We investigated the effect of taking aspirin on the association between cardiovascular risk, WMH burden and cognitive function.
Study design
The study sample was drawn from 318 dementia-free adults aged 67-71 years. Brain magnetic resonance imaging (MRI) scans were acquired from 239 participants.
Main outcome measures
WMH total lesion volumes (TLV) were extracted using the automated lesion segmentation algorithm. We measured cardiovascular risk by calculating ASSIGN score. Cognitive ability was measured using a test of processing speed. We developed structural equation models to test our hypothesis.
Results
Sixty-eight participants (47.1% male, mean age = 68.8 years) reported that they took aspirin. The demographic measures did not differ significantly by aspirin use. Among aspirin users, there was a strong negative association between WMH TLV and cognition (β = -0.43, p-value < 0.001), while in non-users of aspirin the only significant predictor of poorer cognition was cardiovascular risk (β= -0.17, p-value = 0.001).
Conclusions
Aspirin use moderates the negative effect of WMH burden on cognition. Considering WMH burden in addition to cardiovascular risk could improve the prediction of cognitive decline in older adults with aspirin use.
Original language | English |
---|---|
Pages (from-to) | 49-53 |
Number of pages | 5 |
Journal | Maturitas |
Volume | 133 |
Early online date | 7 Jan 2020 |
DOIs | |
Publication status | Published - 1 Mar 2020 |
Keywords
- aspirin
- cardiovascular risk
- brain white matter hyperintensity
- cognition
- older adults
- Aspirin
- Brain white matter hyperintensity
- Cardiovascular risk
- Cognition
- Older adults
- SMALL VESSEL DISEASE
- DEMENTIA
- PREVENTION
- COLLABORATIVE METAANALYSIS
- COGNITIVE FUNCTION
- DECLINE
- HYPERTENSION
- WOMENS HEALTH
- REDUCE